Nebenwirkungen · Ebvallo
Ebvallo 2.8 × 107 – 7.3 × 107 cells/mL dispersion for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-139995 · Präparat HOS-098428
Cytokine release syndrome (CRS) CRS was reported in 2 patients (1.3%) from ALLELE and Study EBV-CTL-201. All patients had Grade 1 CRS presenting with fever with or without chills (including a recurring event after subsequent dosing). All patients recovered. The median time to onset was 9 days (range: 3 to 26 days) including a recurrent event after two successive doses of tabelecleucel. The median duration was 1 day (range: 1 to 3 days). Immunogenicity
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T09:37:00Z · SHA-256 b6b70030408178a0a00d53670d3028d050f247217c320de44f31caafbd3ecd0c · Passage 366dc2290ede214a78f24b57e732c576eaa407bf9c5aa419a92dafdb7191d1ed · Zeichen 9204–9659 im Abschnitt